Telomeres and cancer

Cancer cells have different biological machinery than normal cells. As a cell begins to become cancerous, it divides more often and its telomeres are shortened at a higher rate. Cancerous cells escape senescence/death and conversely, they become immortal with the ability to indefinitely replicate, even with shortened telomeres, resulting in uncontrolled tumor growth.


ONCOCHECK is a unique solution for cancer prognosis and monitoring.

This project has received €3.1 million in funding from the European Union’s Horizon 2020 research and innovation program under grant agreement number 738707.

ONCOCHECK is a two-year clinical project carried out by Life Length. ONCOCHECK’s objective is the clinical validation of Telomere Associated Variables (TAVs) as cancer biomarkers.

With over 7,000 peer-reviewed scientific and clinical journal articles, measuring telomere length as a biomarker for cancer diagnosis and prognosis is well established.




Product development

Thanks to the ONCOCHECK project results, now we are developing new applications in oncology for our TAT technology. All the TAVs (Telomere Associated Variables) obtained have been analyzed using massive data treatment aiming to generate algorithms that would improve cancer management.

The biggest study in terms of sample recruitment was the prostate cancer study. Therefore, the results obtained allowed the analysts to generate better prediction models than in the other pathologies. We are now developing the prostate cancer application as a risk score called ProsTAV.



As for the other studies, preliminary results are very encouraging and we believe we will be soon also exploring the development of new tests for other pathologies as lung or children cancer.


Other studies

Life length in the media


Telomere testing and analysis

What our clients say

Follow us for more information

Contact us

Know more and
let our team guide you